Analysts think SLNO stock price could increase by 185%
Feb 10, 2026, 12:25 PM
-4.41%
What does SLNO do
Soleno Therapeutics, a clinical-stage biopharmaceutical company based in Redwood City, California, focuses on developing novel therapeutics for rare diseases, notably DCCR for Prader-Willi syndrome. DCCR, a once-daily oral tablet, recently completed Phase 3 trials and has received Fast-Track and orphan designations in the U.S. and EU.
15 analysts think SLNO stock price will increase by 184.58%. The current median analyst target is $116.28 compared to a current stock price of $40.86. The lowest analysts target is $60.60 and the highest analyst target is $152.25.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.